Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$821.05 USD

821.05
278,546

-8.38 (-1.01%)

Updated Nov 6, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

    Kevin Cook headshot

    Bull of the Day: Regeneron (REGN)

    Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth

      TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1

      TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.

        Brian Hamilton headshot

        Bear of the Day: AMAG Pharmaceuticals (AMAG)

        Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.

          Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up

          Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.

            Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite

            Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.

              STERIS (STE) Grapples with Headwinds: Should You Dump?

              On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.

                Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

                Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

                  Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates

                  Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.

                    Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip

                    On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.

                      Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat

                      Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

                        Arpita Dutt headshot

                        Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

                        Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.

                          Regeneron Pharmaceuticals (REGN) Shares March Higher, Can It Continue?

                          As of late, it has definitely been a great time to be an investor in Regeneron Pharmaceuticals Inc (REGN).

                            Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene

                            Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene

                              Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates

                              Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.

                                Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss

                                Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03

                                  Ekta Bagri headshot

                                  Regeneron (REGN) Q1 Earnings Misses Estimates

                                  Regeneron???s first-quarter 2017 earnings missed expectations. Our consensus called for EPS of $2.50 and the company reported EPS of $2.16

                                    Kevin Cook headshot

                                    5 Healthcare Innovators I'm Still Buying

                                    When you think long-term about the megatrends in healthcare, it makes picking winners easier

                                      What's in Store for Adverum (ADVM) in Q1 Earnings?

                                      Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

                                        Madeleine Johnson headshot

                                        After Gilead Earnings, Buy These Biotech Stocks

                                        Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.

                                          Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More

                                          Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update

                                            Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

                                              Arpita Dutt headshot

                                              6 FDA Events to Watch Out for in May 2017

                                              Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                                                Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

                                                Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

                                                  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

                                                  Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased